Study of Patritumab Deruxtecan for Advanced HR+/HER2- Breast Cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called patritumab deruxtecan (a targeted therapy) for people with a common type of advanced breast cancer (HR+/HER2-). It's for those whose cancer has grown despite treatment with a CDK4/6 inhibitor plus hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of breast cancer called HR+ (hormone receptor positive) and HER2- (human epidermal growth factor receptor 2 negative).
- Your breast cancer is either advanced (can't be removed with surgery) or has spread to other parts of the body (metastatic).
- You have received a CDK4/6 inhibitor (like Ibrance or Kisqali) with hormone therapy, and your cancer got worse during that treatment or within 2 years of finishing it.
- You must not have had more than one line of treatment for advanced breast cancer (except the CDK4/6 inhibitor plus hormone therapy).
- You cannot have certain other health conditions, like uncontrolled heart disease, lung problems needing oxygen, or a history of severe lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, patritumab deruxtecan, combined with other cancer treatments for people with advanced HER2+ breast cancer that cannot be removed by surgery. It may be an option if you have already tried other HER2-targeted therapies.
This trial tests a combination of targeted therapies (patritumab deruxtecan plus pembrolizumab) along with other anticancer drugs for people with a high-risk type of early-stage breast cancer that is either triple-negative or has very low hormone receptors and is HER2-negative. The goal is to see if this approach can help prevent the cancer from coming back.
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
This trial tests a new combination of two targeted drugs (patritumab deruxtecan and trastuzumab deruxtecan) for people with hormone receptor-positive breast cancer that has low or ultralow levels of HER2 and has spread or cannot be removed by surgery. The goal is to see if the combination works better than current treatments.
This trial tests a new drug (patritumab deruxtecan) for people with advanced or spreading cancers of the digestive system (including colorectal, bile duct, liver, and stomach/esophageal cancers). The goal is to see if it can shrink tumors or stop them from growing.
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.